within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01D_OtherBetaLactamAntibacterials.J01DC09_Cefmetazole;

model Cefmetazole
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 4.444444444444445e-07,
    adminDuration = 600,
    adminMass = 1000 / 1000000,
    adminCount = 1,
    Vd = 0.0002,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Cefmetazole</td></tr><tr><td>ATC code:</td><td>J01DC09</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>1000</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.2</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.6</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Cefmetazole is a second-generation cephamycin antibiotic used for the treatment of infections caused by susceptible Gram-positive and Gram-negative bacteria. It is used primarily in Japan and some Asian countries for respiratory, urinary, and intra-abdominal infections, but is not widely approved in the US or EU.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after single intravenous administration.</p><h4>References</h4><ol><li><p>Komatsu, T, et al., &amp; Atsuda, K (2022). Timing of re-dosing based on population pharmacokinetic-pharmacodynamics target attainment analysis of cefmetazole in subjects undergoing lower gastrointestinal surgery. <i>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</i> 28(8) 1105–1111. DOI:<a href=\"https://doi.org/10.1016/j.jiac.2022.03.024\">10.1016/j.jiac.2022.03.024</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35400549/\">https://pubmed.ncbi.nlm.nih.gov/35400549</a></p></li><li><p>Borin, MT, et al., &amp; Smith, TC (1990). Pharmacokinetics and dose proportionality of cefmetazole in healthy young and elderly volunteers. <i>Antimicrobial agents and chemotherapy</i> 34(10) 1944–1948. DOI:<a href=\"https://doi.org/10.1128/AAC.34.10.1944\">10.1128/AAC.34.10.1944</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2291659/\">https://pubmed.ncbi.nlm.nih.gov/2291659</a></p></li><li><p>Tomizawa, A, et al., &amp; Atsuda, K (2017). Optimal dosage of cefmetazole for intraoperative antimicrobial prophylaxis in patients undergoing surgery for colorectal cancer. <i>Journal of pharmaceutical health care and sciences</i> 3 1–None. DOI:<a href=\"https://doi.org/10.1186/s40780-016-0071-6\">10.1186/s40780-016-0071-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28074152/\">https://pubmed.ncbi.nlm.nih.gov/28074152</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J01DC09 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Cefmetazole;
